Other Events ·
Clearmind Medicine Inc. announced the initiation of Phase IIa of its double-blind, placebo-controlled clinical trial…
CMNDClearmind Medicine Inc.
Clearmind Medicine Inc. announced the initiation of Phase IIa of its double-blind, placebo-controlled clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD). The company has enrolled six patients to date: three at Tel Aviv Sourasky Medical Center and three at Hadassah Medical Center in Jerusalem. This marks the start of the first multiple-dose treatment phase of Part C, following the successful completion of the trial's initial safety part in healthy volunteers and a positive assessment by an independent Data and Safety Monitoring Board. Clearmind Medicine Inc. is a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for neuropsychiatric, metabolic, and addiction disorders.